EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A PD1 ‐ CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD ‐ L1 and CD137 Separately

Runze Xia iD, Emily Pauline Nickles, Yu Mei iD, Thamizhanban Manoharan, Yi Tian Png, Beijia Liu iD, Rui Sun, Kang Yi Lee, Gloryn Chia iD, Chwee Ming Lim, Herbert Schwarz iD

Immunology · 2026-12 · 179 (4) · 579-593

DOI: 10.1111/imm.70189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, online erschienen am 10.08.2026. Verfasst von Runze Xia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: 4-1BB Ligand, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Recombinant Fusion Proteins. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation Singapore, National Medical Research Council, Singapore, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold’ tumours. To overcome this limitation, we developed a dual targeting human PD1‐CD137L (hPD1‐CD137L) fusion protein that blocks PD‐L1–PD1 inhibitory signalling and simultaneously delivers CD137‐mediated T cell costimulation. The fusion protein was produced with high purity and demonstrated specific binding to PD‐L1‐expressing tumour cells and CD137‐positive T cells. The hPD1‐CD137L retained a stable multimeric structure under acidic conditions and during prolonged storage, supporting its suitability for systemic administration and activity within the tumour microenvironment. Functionally, hPD1‐CD137L enhanced T cell activation, as evidenced by increased NF‐κB signalling and activation marker expression, and promoted robust tumour cell cytolysis in both 2D and 3D co‐culture systems. Anti‐tumour activity was observed across multiple tumour models with varying PD‐L1 expression, including nasopharyngeal carcinoma (NPC), rhabdomyosarcoma, lung carcinoma and patient‐derived colorectal cancer organoids. Notably, hPD1‐CD137L enhanced cytolysis of C666 NPC cells by patient‐derived tumour‐infiltrating lymphocytes at low effector‐to‐target ratios, and was more potent than a combination of an anti‐PD‐1 antibody and a CD137 agonist. In vivo, PBMC‐humanised NSG mice tolerated hPD1‐CD137L without significant weight loss, systemic inflammation or survival impact. Subsequent efficacy study in PBMC‐humanised, Rd18 rhabdomyosarcoma‐engrafted or C666 nasopharyngeal carcinoma‐engrafted NSG mice showed tumour growth suppression without overt toxicity. This study validates a human PD1‐CD137L fusion protein as a potent drug candidate for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

4-1BB LigandB7-H1 AntigenProgrammed Cell Death 1 ReceptorRecombinant Fusion ProteinsTumor Necrosis Factor Receptor Superfamily, Member 9NeoplasmsImmune Checkpoint InhibitorsHumansAnimalsCell Line, TumorLymphocyte ActivationMiceTumor MicroenvironmentT-LymphocytesSignal TransductionXenograft Model Antitumor AssaysFemale

Stichwörter der Autor:innen

CD137 ligandPD‐1costimulationimmune evasionimmunotherapytumour microenvironment

Substanzen

4-1BB LigandB7-H1 AntigenProgrammed Cell Death 1 ReceptorRecombinant Fusion ProteinsTumor Necrosis Factor Receptor Superfamily, Member 9CD274 protein, humanPDCD1 protein, humanTNFSF9 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • NUS Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.
  • NUSMED Immunology Translational Research Programme, National University of Singapore, Singapore, Singapore.
  • Integrative Sciences and Engineering Programme, National University of Singapore, Singapore, Singapore.
  • Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Runze Xia, Yu Mei, Beijia Liu, Gloryn Chia, Herbert Schwarz

Förderung

  • National Research Foundation Singapore
  • National Medical Research Council, Singapore
  • National Medical Research Council

Zitieren

APA

Xia, R., Nickles, E. P., Mei, Y., Manoharan, T., Png, Y. T., Liu, B., Sun, R., Lee, K. Y., Chia, G., Lim, C. M., & Schwarz, H. (2026). A PD1 ‐ CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD ‐ L1 and CD137 Separately. Immunology, 179(4), 579-593. https://doi.org/10.1111/imm.70189

Vancouver

Xia R, Nickles EP, Mei Y, Manoharan T, Png YT, Liu B, et al. A PD1 ‐ CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD ‐ L1 and CD137 Separately. Immunology. 2026;179(4):579-593. doi:10.1111/imm.70189

BibTeX
@article{Xia2026,
  author = {Xia, Runze and Nickles, Emily Pauline and Mei, Yu and Manoharan, Thamizhanban and Png, Yi Tian and Liu, Beijia and Sun, Rui and Lee, Kang Yi and Chia, Gloryn and Lim, Chwee Ming and Schwarz, Herbert},
  title = {A PD1 ‐ CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD ‐ L1 and CD137 Separately},
  journal = {Immunology},
  year = {2026},
  volume = {179},
  number = {4},
  pages = {579--593},
  doi = {10.1111/imm.70189}
}
Kostenlos starten →